EVG.L - Evgen Pharma plc

LSE - LSE Delayed price. Currency in GBp

Evgen Pharma plc

The Colony
Altrincham Road
Wilmslow SK9 4LY
United Kingdom
44 16 2546 6591
http://www.evgen.com

SectorHealthcare
IndustryBiotechnology
Full-time employees7

Key executives

NameTitlePayExercisedYear born
Dr. Stephen J. FranklinCEO & Exec. Director228.3kN/AN/A
Mr. Richard Anthony MoulsonCFO & Exec. Director93.68kN/A1962
Ms. Liz JenkinsRegulatory ConsultantN/AN/AN/A
Dr. Thomas MorrisConsultant & Medical Advisor of OncologyN/AN/AN/A
Prof. Albena Dinkova-KostovaIndependent Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.

Corporate governance

Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more